FILE - A rare fragment of a Dodo femur bone is displayed for photographs next to an image of a member of the extinct bird species at Christie's auction house's premises in London, March 27, 2013. Colossal Biosciences has raised an additional $150 million from investors to develop genetic technologies that the company claims will help to bring back some extinct species, including the dodo and the woolly mammoth. Other scientists are skeptical that such feats are really possible, or even advisable for conservation.
Image Credit: (AP Photo/Matt Dunham, File)
January 31, 2023 - 9:00 PM
WASHINGTON (AP) — The dodo bird isn’t coming back anytime soon. Nor is the woolly mammoth. But a company working on technologies to bring back extinct species has attracted more investors, while other scientists are skeptical such feats are possible or a good idea.
Colossal Biosciences first announced its ambitious plan to revive the woolly mammoth two years ago, and on Tuesday said it wanted to bring back the dodo bird, too.
“The dodo is a symbol of man-made extinction,” said Ben Lamm, a serial entrepreneur and co-founder and CEO of Colossal. The company has formed a division to focus on bird-related genetic technologies.
The last dodo, a flightless bird about the size of a turkey, was killed in 1681 on the Indian Ocean island of Mauritius.
The Dallas company, which launched in 2021, also announced Tuesday it had raised an additional $150 million in funding. To date, it has raised $225 million from wide-ranging investors that include United States Innovative Technology Fund, Breyer Capital and In-Q-Tel, the CIA’s venture capital firm which invests in technology.
The prospect of bringing the dodo back isn’t expected to directly make money, said Lamm. But the genetic tools and equipment that the company develops to try to do it may have other uses, including for human health care, he said.
For example, Colossal is now testing tools to tweak several parts of the genome simultaneously. It’s also working on technologies for what is sometimes called an “artificial womb,” he said.
The dodo’s closest living relative is the Nicobar pigeon, said Beth Shapiro, a molecular biologist on Colossal’s scientific advisory board, who has been studying the dodo for two decades. Shapiro is paid by the Howard Hughes Medical Institute, which also supports The Associated Press’ Health and Science Department.
Her team plans to study DNA differences between the Nicobar pigeon and the dodo to understand “what are the genes that really make a dodo a dodo,” she said.
The team may then attempt to edit Nicobar pigeon cells to make them resemble dodo cells. It may be possible to put the tweaked cells into developing eggs of other birds, such as pigeons or chickens, to create offspring that may in turn naturally produce dodo eggs, said Shapiro. The concept is still in an early theoretical stage for dodos.
Because animals are a product of both their genetics and their environment — which has changed dramatically since the 1600s — Shapiro said that “it’s not possible to recreate a 100% identical copy of something that’s gone.”
Other scientists wonder if it’s even advisable to try, and question whether “de-extinction” diverts attention and money away from efforts to save species still on Earth.
“There’s a real hazard in saying that if we destroy nature, we can just put it back together again — because we can’t,” said Duke University ecologist Stuart Pimm, who has no connection to Colossal.
“And where on Earth would you put a woolly mammoth, other than in a cage?” asked Pimm, who noted that the ecosystems where mammoths lived disappeared long ago.
On a practical level, conservation biologists familiar with captive breeding programs say that it can be tricky for zoo-bred animals to ever adapt to the wild.
It helps if they can learn from other wild animals of their kind — an advantage that potential dodos and mammoths won’t have, said Boris Worm, a biologist at the University of Dalhousie in Halifax, Nova Scotia, who has no connection to Colossal.
“Preventing species from going extinct in the first place should be our priority, and in most cases, it’s a lot cheaper,” said Worm.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
News from © The Associated Press, 2023